EP233: Garlic, Devices, Renal Denervation, and Appolo

Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I’m a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients. Podcast Summary Introduction Dr. Warrick is a practicing cardiologist and author dedicated to educating patients about heart health and the latest advances in cardiac care. In this episode, he discusses four recent cardiovascular breakthroughs: aged black garlic's blood pressure effects, smart wearable devices for detecting atrial fibrillation and sleep apnea, renal artery denervation for treatment-resistant hypertension, and a new RNA-based therapy for lowering lipoprotein(a). Key Takeaways: Aged black garlic (ABG) containing S-allylcysteine (SAC) demonstrated the ability to reduce diastolic blood pressure by approximately 6 mmHg in a Spanish clinical trial of 67 healthy men. A 5-6 mmHg reduction in diastolic blood pressure correlates to roughly 40% reduction in stroke risk and 30% reduction in heart attack risk, making aged black garlic's effects potentially very significant. Wearable smart devices using photoplethysmography (PPG) technology can effectively detect atrial fibrillation, identifying 0.4% prevalence in a low-risk population over four years with 93% detection accuracy. Advanced algorithms in smartwatches can now assess multiple cardiovascular and respiratory parameters including obstructive sleep apnea, with detection of OSA in approximately 18,000 out of 900,000 tested users. The SPIRAL hypertension trial demonstrated that renal artery denervation (ablating sympathetic nerves in renal arteries) maintains its blood pressure-lowering effects of 10 mmHg systolic and 5 mmHg diastolic reduction at three years post-intervention. The SPIRAL trial used a sham procedure as a placebo control, ensuring results exceeded pure placebo effects and validating the true effectiveness of the intervention. The Apollo trial revealed that a small interfering RNA (siRNA) therapy achieved nearly 98% lowering of lipoprotein(a), a dangerous LDL-like particle associated with premature coronary artery disease and aortic stenosis. The siRNA therapy additionally provided a 25% reduction in LDL cholesterol, offering dual cardiovascular benefits in treating this emerging high-risk cholesterol particle.